AVEED (testosterone undecanoate) by Verity Pharmaceuticals is androgens, including testosterone and dihydrotestosterone (dht) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. First approved in 2014.
Drug data last refreshed 2h ago · AI intelligence enriched 3d ago
AVEED is a testosterone undecanoate injectable suspension approved for treatment of male hypogonadism, a condition characterized by insufficient testosterone production. The drug restores testosterone levels by replacing deficient endogenous hormone, enabling normal development and maintenance of male sex characteristics. It addresses both primary hypogonadism (gonadal defects) and secondary hypogonadism (hypothalamic/pituitary failure).
Product is approaching loss of exclusivity with modest Medicare spend; expect contraction of commercial team and shift toward defensive positioning.
androgens, including testosterone and dihydrotestosterone (DHT) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis, and scrotum; the…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism
Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations
Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men
Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men
Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism
Worked on AVEED at Verity Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
AVEED represents a declining commercial opportunity with zero currently linked job openings, making it an unattractive career destination for growth-oriented professionals. Roles on this product focus on defending market share and managing transition to generic competition rather than expansion or innovation.